[go: up one dir, main page]

MA31849B1 - Nouveaux dérivés de pyrimidine - Google Patents

Nouveaux dérivés de pyrimidine

Info

Publication number
MA31849B1
MA31849B1 MA32838A MA32838A MA31849B1 MA 31849 B1 MA31849 B1 MA 31849B1 MA 32838 A MA32838 A MA 32838A MA 32838 A MA32838 A MA 32838A MA 31849 B1 MA31849 B1 MA 31849B1
Authority
MA
Morocco
Prior art keywords
pyrimidine derivatives
new pyrimidine
new
preparation
compounds
Prior art date
Application number
MA32838A
Other languages
Arabic (ar)
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Boris Mathys
Claus Mueller
Oliver Nayler
Beat Steiner
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31849B1 publication Critical patent/MA31849B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur de nouveaux dérivés de pyrimidine, sur leur préparation et sur leur utilisation en tant que composés pharmaceutiquement actifs. Lesdits composés agissent particulièrement en tant qu'agents immunomodulants.
MA32838A 2007-11-01 2010-05-17 Nouveaux dérivés de pyrimidine MA31849B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054437 2007-11-01
PCT/IB2008/054543 WO2009057079A2 (fr) 2007-11-01 2008-10-31 Nouveaux dérivés de pyrimidine

Publications (1)

Publication Number Publication Date
MA31849B1 true MA31849B1 (fr) 2010-11-01

Family

ID=40577704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32838A MA31849B1 (fr) 2007-11-01 2010-05-17 Nouveaux dérivés de pyrimidine

Country Status (18)

Country Link
US (1) US8299086B2 (fr)
EP (1) EP2217594B1 (fr)
JP (1) JP5517944B2 (fr)
KR (1) KR20100092473A (fr)
CN (1) CN101970430B (fr)
AR (1) AR069146A1 (fr)
AU (1) AU2008320374A1 (fr)
BR (1) BRPI0818804A2 (fr)
CA (1) CA2700917A1 (fr)
ES (1) ES2449749T3 (fr)
IL (1) IL205425A0 (fr)
MA (1) MA31849B1 (fr)
MX (1) MX2010004576A (fr)
NZ (1) NZ585775A (fr)
RU (1) RU2010121969A (fr)
TW (1) TW200920746A (fr)
WO (1) WO2009057079A2 (fr)
ZA (1) ZA201003875B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511827B (zh) * 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
CA2661315C (fr) * 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MX2009002781A (es) 2006-09-15 2009-03-30 Reviva Pharmaceuticals Inc Sintesis, metodos de uso y composiciones de cicloalquilmetilaminas .
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN101522645B (zh) * 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
SI2125797T1 (sl) * 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
BRPI0815190A2 (pt) * 2007-08-17 2015-03-31 Actelion Pharmaceuticals Ltd Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
US20110046170A1 (en) * 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
EP2262799B1 (fr) * 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Composés de pyridine
AU2009220893A1 (en) * 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
NZ588438A (en) * 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
WO2010085581A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
JP2012515789A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー スフィンゴシン−１−リン酸アゴニストとしてのピラゾール−１，２，４−オキサジアゾール誘導体
US8404672B2 (en) 2009-01-23 2013-03-26 Bristol-Meyers Squibb Company Substituted heterocyclic compounds
EP2454255B1 (fr) 2009-07-16 2013-11-06 Actelion Pharmaceuticals Ltd. Dérivés de pyridin-4-yle comme agonistes de s1p1/edg1
US8399451B2 (en) * 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
KR20130036171A (ko) 2009-10-29 2013-04-11 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 헤테로시클릭 화합물
EP2560969B1 (fr) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company Amides du 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-acide mandelique comme agonistes du sphingosin-1-phosphate 1 recepteur
ES2539256T3 (es) 2010-07-20 2015-06-29 Bristol-Myers Squibb Company Compuestos de 3-fenil-1,2,4-oxadiazol sustituidos
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
ES2525298T3 (es) 2010-11-03 2014-12-19 Bristol-Myers Squibb Company Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares
ES2544086T3 (es) 2011-01-19 2015-08-27 Actelion Pharmaceuticals Ltd. Derivados de 2-metoxi-piridin-4-ilo
ES2726807T3 (es) * 2011-12-30 2019-10-09 Reviva Pharmaceuticals Inc Composiciones, síntesis y métodos de uso de derivados de 1-[1-fenil-ciclobutil]isobutilamina
UY35338A (es) 2013-02-21 2014-08-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
MA38482B1 (fr) 2013-03-15 2018-11-30 Idorsia Pharmaceuticals Ltd Dérivés de pyridin-4-yle agonistes du recepteur de la sphingosine-1-phosphate utilises pour traiter, par ex. Syndromes auto-immuns, sclerose en plaques, colite ulcereuse, psoriasis et migraine
AR101591A1 (es) 2014-08-20 2016-12-28 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos
PH12017502097B1 (en) 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2017004609A1 (fr) * 2015-07-02 2017-01-05 Exelixis, Inc. Modulateurs thiadiazole de s1p et procédés de fabrication et d'utilisation
ES2859478T3 (es) 2016-09-02 2021-10-04 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos sustituidos
WO2019032631A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'éther d'oxime
WO2019032632A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'alkylphényle

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015583A1 (fr) 1990-04-05 1991-10-17 The American National Red Cross Famille de proteines apparentee a une proteine precoce immediate exprimee par des cellules endotheliales humaines durant la differenciation
EP1070080A4 (fr) 1998-03-09 2004-12-29 Smithkline Beecham Corp POLYNUCLEOTIDES ET POLYPEPTIDES D'EDG-1c HUMAIN ET LEURS PROCEDES D'UTILISATION
JP3790472B2 (ja) 1999-08-19 2006-06-28 エヌピーエス ファーマシューティカルズ インコーポレーテッド ヘテロ多環式化合物および代謝型グルタミン酸受容体アンタゴニストとしてのその使用
US6559140B2 (en) * 2000-03-09 2003-05-06 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
HRP20040098B1 (en) * 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
CA2472713C (fr) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylates, phosphinates, phosphonates et tetrazoles en tant qu'agonistes de recepteur edg
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
EP1554269A1 (fr) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles et thiazoles presentant des activites d'inhibition des proteines kinases
WO2004035538A1 (fr) 2002-10-15 2004-04-29 Merck & Co., Inc. Procede de fabrication de l'acide azetidine-3-carboxylique
JP2006528980A (ja) * 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
CA2539438A1 (fr) 2003-10-01 2005-04-14 Merck And Co., Inc. 1,2,4-oxadiazoles substitues 3,5-aryle, heteroaryle ou cycloalkyle servant d'agonistes du recepteur s1p
WO2005058848A1 (fr) 2003-12-17 2005-06-30 Merck & Co., Inc. Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
EP1758579A1 (fr) 2004-05-29 2007-03-07 7TM Pharma A/S Ligands des recepteurs crth2 a usages medicaux
EP1804793A4 (fr) 2004-10-22 2010-03-31 Merck Sharp & Dohme Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
CA2590939C (fr) * 2004-12-17 2011-10-18 Amgen Inc. Composes d'aminopyrimidine et procedes d'utilisation correspondants
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
JP2008546836A (ja) 2005-06-28 2008-12-25 アストラゼネカ アクチボラグ 新規な用途
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
GB0601744D0 (en) * 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2007098474A1 (fr) 2006-02-21 2007-08-30 University Of Virginia Patent Foundation Composés de phényl-cycloalkyl contenant des structures à anneau hétérocyclique
CN101511827B (zh) 2006-09-07 2012-02-01 埃科特莱茵药品有限公司 作为免疫调制剂的吡啶-4-基衍生物
CA2661315C (fr) 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
CN101522645B (zh) 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
WO2008091967A1 (fr) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Composés chimiques
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
EP2262799B1 (fr) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Composés de pyridine
NZ588438A (en) 2008-03-07 2012-05-25 Actelion Pharmaceuticals Ltd Pyridin-2-yl oxadiazole derivatives as immunomodulating agents
AU2009220893A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
DK2291080T3 (en) 2008-05-14 2015-12-07 Scripps Research Inst Novel modulator of sphingosinphosphatreceptorer
EP2454255B1 (fr) 2009-07-16 2013-11-06 Actelion Pharmaceuticals Ltd. Dérivés de pyridin-4-yle comme agonistes de s1p1/edg1

Also Published As

Publication number Publication date
EP2217594A2 (fr) 2010-08-18
EP2217594B1 (fr) 2014-01-08
CN101970430A (zh) 2011-02-09
AR069146A1 (es) 2009-12-30
NZ585775A (en) 2011-12-22
ZA201003875B (en) 2012-08-29
WO2009057079A3 (fr) 2009-12-03
CN101970430B (zh) 2013-05-08
JP2011502980A (ja) 2011-01-27
CA2700917A1 (fr) 2009-05-07
AU2008320374A1 (en) 2009-05-07
RU2010121969A (ru) 2011-12-10
MX2010004576A (es) 2010-05-17
US20100234346A1 (en) 2010-09-16
US8299086B2 (en) 2012-10-30
KR20100092473A (ko) 2010-08-20
IL205425A0 (en) 2010-12-30
JP5517944B2 (ja) 2014-06-11
WO2009057079A2 (fr) 2009-05-07
TW200920746A (en) 2009-05-16
BRPI0818804A2 (pt) 2015-04-22
ES2449749T3 (es) 2014-03-21

Similar Documents

Publication Publication Date Title
MA31849B1 (fr) Nouveaux dérivés de pyrimidine
MA31953B1 (fr) Nouveaux derives du thiophene.
MA30765B1 (fr) Derives innovants du thiophene
MA33528B1 (fr) Derives pyridin-4-yliques
ATE447568T1 (de) Neue pyrinderivate
MA31290B1 (fr) Derives d'amino-pyridine comme agonistes du recepteur s1p1/edg1
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
MA31988B1 (fr) Derives d'aminopyrazole
TW200716552A (en) Novel thiophene derivatives
MA32711B1 (fr) Pyrrolidine-2-carboxamides substitues
BRPI0514474A (pt) multiparticulados
TW200942524A (en) Novel aminomethyl benzene derivatives
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
TW200738670A (en) Novel thiophene derivatives
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
MY145074A (en) Thiazolidin-4-one derivatives
DK1819227T3 (da) Farmaceutisk formulering af decitabin
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
TW200942530A (en) Pyridine compounds
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
DE602005023197D1 (de) -muscarinrezeptors
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments